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creativecommons.org/ease (AD) from preclinical to symptomatic phases, it is increasingly important to quantify AD
severity using methods that capture underlying pathophysiology.
Methods: We derived an AD severity measure based on biomarkers from brain imaging, neuropa-
thology, and cognitive testing using latent variable modeling. We used data from ADNI-1
(N 5 822) and applied findings to BIOCARD study (N 5 349). We evaluated criterion validity for
distinguishing diagnostic groups and construct validity by evaluating rates of change in AD severity.
Results: The AD severity factor cross-sectionally distinguishes cognitively normal participants from
MCI (AUC5 0.87) and AD dementia (AUC5 0.94). Among ADNI MCI subjects, worsening scores
predict faster progression to AD dementia (HR 5 1.17; 95% CI, 1.13–1.22). In ADNI and
BIOCARD, the pace of change in AD severity is steepest among progressors, with persisting
differences by baseline diagnosis.
Discussion: Our content-valid latent variable measurement model is a reasonable approach for
grading AD severity across a broad spectrum beginning at preclinical stages of AD.
 2016 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Alzheimer’s disease; Clinical trials; Measurement; Item response theory; Cognitive testing; Imaging;Longitudinal follow-up1. Introduction
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licenses/by-nc-nd/4.0/).with changes in biomarkers that capture various aspects of
the underlying neuropathology [1,2]. AD develops over
decades [3,4] and has a long prodromal period [5,6]. The
clinical manifestations of AD are often evident only after
many years of accumulating neuropathology.
A multitude of AD biomarkers including those derived
from brain imaging, cerebrospinal fluid, and neuropsycho-
logical testing have been identified which provide distinct
information about the pathophysiology and clinical course
of AD. A highly influential theoretical model has provided
a framework for conceptualizing the pathological cascade
of AD [1]. This dynamic biomarkers model proposes that
the pathologic cascade of AD begins with abnormal amyloid
processing, resulting in build-up of amyloid beta proteination. This is an open access article under the CC BY-NC-ND license (http://
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combination has neurotoxic effects resulting in cellular
dysfunction and death, brain atrophy, and impaired neuro-
psychological function. This process culminates in clinical
symptoms and functional disability [1].
Biomarkers in the dynamic biomarkers model are hy-
pothesized to provide information over a spectrum from pre-
clinical to clinical stages of AD. Evidence suggests,
however, that no single biomarker provides sufficient infor-
mation to capture the underlying severity of disease across
the entire spectrum. Several efforts are thus underway to
objectively and quantitatively combine multiple biomarkers
to characterize the clinico-pathophysiological severity of
AD [7,8]. The main goal of this study is to operationalize
such a method objectively and quantitatively and to
evaluate its validity.
Features of the dynamic biomarkers hypothesis relevant
for its operationalization are the prevalence of multiple dis-
ease severity markers, thought to represent relationships be-
tween disease severity markers and disease stage and the
characterization of the phase of disease. First, levels of dis-
ease severity markers underlying physiological mechanisms
indicate worsening AD severity over time. Different markers
worsen from normal to abnormal levels during different
phases of AD, ranging from cognitively normal, through
mild cognitive impairment (MCI), to clinical dementia. A
second feature of the dynamic biomarkers model is the hy-
pothesized sigmoidal (s-shaped) relationship between each
disease severity marker and disease stage. In the mid-
range of the disease severity marker response, its relation-
ship with underlying disease stage is presumed linear, but
the distribution at its tails asymptotes toward normal/
abnormal response levels. Different disease severity markers
have different dynamic ranges. For example, while deposi-
tion of Ab1–42 is initially occurring, there may be no change
in memory. Later, while memory worsens, it is hypothesized
that less Ab1–42 deposition is taking place relative to earlier
disease stages. A third key feature of the dynamic bio-
markers model is disease stage on the x-axis. Neither time
nor age is necessary to describe the advancing disease
course, but some quantity (i.e., underlying disease severity)
not directly measureable is. Jack et al. [9] suggested a latent
variable model, as implemented in this study, may suffi-
ciently represent AD severity and its relationship to disease
severity markers.
The dynamic biomarkers model is almost immediately
recognizable as a latent variable model. Latent variable
models relate item responses on observed variables to a
latent, or unobserved, variable using probabilistic models.
Severity of underlying pathology is the latent variable. A
latent variable is not directly observable but is presumed to
causally influence reflective indicators (disease severity
markers). The response scale of disease severity markers
and sigmoidal response curve shape leads naturally to
response variable discretization [10] and graded response
variable modeling [11]. Latent variable modeling character-izes aspects of persons (level of latent AD severity) and
aspects of latent variable indicators (disease severity
markers). This approach quantifies underlying AD pathol-
ogy in persons without frank impairment.
Our main goal was to operationalize the dynamic bio-
markers hypothesis. We present an objective and quantita-
tive method for integrating multiple biomarkers and other
disease severity markers of AD into a global measure of
AD severity using a latent trait framework based in measures
from cerebrospinal fluid, structural neuroimaging, neuropsy-
chological performance, and ratings of functional impair-
ment. We demonstrate the potential utility of the measure
of AD severity by using it to describe differences between
clinically defined diagnostic groups—normal, MCI, and
AD dementia—and to predict future progression to more
impaired clinical states. We suggest applications of the
model for research and clinical purposes, as well as weak-
nesses and opportunities for extending the model. We used
data from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) study to derive the model and applied the findings
in the BIOCARD study, both longitudinal studies in which
a range of biomarkers was collected.2. Methods
2.1. Participants
We used data collected in the ADNI and BIOCARD
studies. ADNI (adni.loni.usc.edu) was launched in 2003 as
a public-private partnership, led by Principal Investigator
Michael W. Weiner, MD. The primary goal of ADNI was
to test whether biological markers could be used to improve
measurement of clinical and neuropsychological progression
in clinical trials. In these analyses, we used data from ADNI-
1. For up-to-date information, see www.adni-info.org.
The BIOCARD study initially recruited 349 cognitively
normal middle-aged persons starting in 1995, most of
whom by design had a first-degree relative with dementia.
The primary goal of the study was to identify early markers
of progression to MCI due to AD in cognitively normal peo-
ple. Participants were recruited by the Geriatric Psychiatry
branch of the Intramural Program of the National Institute
of Mental Health. The study was stopped in 2005, and in
2009 was reestablished by a research team at the Johns Hop-
kins School of Medicine. Clinical assessments and cognitive
testing were completed annually; MRI scans, cerebrospinal
fluid, and blood specimens were collected approximately
every 2 years. Further details are available elsewhere [12].
Importantly, BIOCARD is smaller in sample size and has
less heterogeneity in AD severity than ADNI, but BIO-
CARD has greater longitudinal follow-up.
ADNI data could be characterized as a cross-sectional
study with longitudinal follow-up in that participants in diag-
nostic groups were very different from each other at baseline
on cognitive, imaging, and cerebrospinal fluid (CSF) out-
comes, and the study has not yet followed people long enough
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ables relative to baseline differences [13]. Our reason for us-
ing these data is that ADNI provides a wider spread, albeit
from cross-sectional information, of AD biomarker levels
thank BIOCARD and thus presumably better measurement
estimation in the impaired range of AD severity.
2.2. Disease severity markers
We used biomarkers from each dimension proposed by
Jack et al. [1]. Concentrations of Ab1–42 and phosphorylated
tau (P-tau) were analyzed from CSF samples in both ADNI
and BIOCARD. ADNI and BIOCARD both used the xMAP
platform (Luminex Corp, Austin, Texas) and INNO-BIA
AlzBio3 research-use-only reagents [14,15]. In ADNI and
BIOCARD, measures of hippocampal volume were
available from MRI scans. In analyses, we residualized
hippocampal volume by intracranial volume [16].
The ADNI baseline neuropsychological assessment pro-
cedures incorporated a wide range of cognitive measures
[17]. Tests included the auditory verbal learning test
(AVLT) [18] and the digit symbol substitution test [19].
Cognitive assessments in BIOCARD were also extensive
[12]; they included the California verbal learning test
(CVLT) [20] and the Digit Symbol Substitution Test. The
digit symbol substitution test is a multifactorial test shown
to be a significant predictor of progression from normal
cognition to mild impairment [12]. We used linear equating
to scale the CVLT in BIOCARD to the AVLT [21]. To repre-
sent clinical functioning, we used the Functional Activities
Questionnaire (FAQ) available from both studies [22].
2.3. Scale of the response of the disease severity markers
The disease severity markers used here are not on the
same scale. Placing them on a common scale can be accom-
plished using transformation functions. We broke contin-
uous indicators into nine categories with equally-spaced
intervals to preserve floor and ceiling effects if present
(Supplementary Table 2). Cut points used to categorize dis-
ease severity markers were spaced using their empirical dis-
tributions in ADNI and are thus designed to be spread out
along the range of the latent trait, unconnected to clinical di-
agnoses. In a sensitivity analysis, we implemented a normal-
ization transformation function by placing each disease
severity marker on a scale from 0 to 1.
2.4. Analysis plan
Wedeveloped a latent trait model of AD severity based on
disease severity markers guided by the dynamic biomarkers
hypothesis [1]. We then empirically validated the model by
contrasting the level and change of the derived severity score
with clinical diagnosis (Normal, MCI, and AD dementia).
We contrasted the score’s ability to predict risk of progres-
sion to a more impaired clinical state relative to its compo-
nent disease severity markers. We applied the findingsfrom a cohort that represents a broad range of disease
(ADNI) to a cohort designed to focus on the preclinical
phase of AD (BIOCARD). We used both samples because
although ADNI includes a wide spread of disease severity
marker levels, BIOCARD features a younger sample at
earlier stages of risk for dementia.
2.4.1. Model derivation
To evaluate dimensionality of the AD severity indicators,
we used parallel analysis with scree plots [23]. We then
developed the latent variable measurement model of AD
severity using a 2-step approach in ADNI and BIOCARD.
The approach accounts for variance and covariance among
AD signs and symptoms and addresses the challenge of
repeated measures. First, we fit a factor analysis measure-
ment model using baseline data in ADNI, evaluating fit by
the empirical or pseudo-r2, which is the squared correlation
between observed and model-estimated indicator values that
represents the proportion of variability explained by the
model [24]. The model used statistically appropriate poly-
choric correlation matrices and is equivalent to a logistic
graded response item response theory model [25,26]. This
equation describes the relationship between categorized
biomarkers u and the AD severity factor q:
PijðqÞ5e1:7aiðq2bijÞh
11e1:7aiðq2bijÞ
i
The expected probability P(q) of scoring in or above cate-
gory j of item i is a function of a discrimination parameter ai,
a set of item difficulty or threshold parameters bij, and the
latent variable q for AD severity.
Next, we ran the model using all follow-up data in ADNI
in which parameters (factor loadings and thresholds) were
constrained to their values in the baseline model as a latent
variable scoring device. We used the same procedure in
ADNI and in BIOCARD. After evaluating model fit in both
studies, we scaled the factor in BIOCARD to that in ADNI
by fixingmodel parameters inBIOCARD tovalues estimated
in the baseline ADNImodel.We scored BIOCARD to ADNI
instead of vice versa because the greater range of disease
severity markers in ADNI provided more reliable estimates.
The latent trait, estimated as a factor score for each visit
with available disease severity marker data, represents a sub-
ject’s level of AD severity at a visit, is defined based on the
covariance of variables in a way analogous to factor anal-
ysis: our approach can be described as a generalized linear
item response theory approach [27]. We used Mplus version
7.3 [28].2.4.2. Model validation
We first contrasted the level and change of the derived
severity score with baseline clinical diagnosis from ADNI
(AD dementia, MCI, cognitively normal) and risk of
progression to a more impaired clinical state.
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severity factor distinguished diagnostic groups in ADNI
and BIOCARD using receiver operator characteristic ana-
lyses. We compared area under the curve (AUC) with
component disease severity markers.
Third, we determined how well baseline levels of the AD
severity factor among cognitively normal individuals predict
progression to MCI or to AD. We contrasted these associa-
tions with those of components of the AD severity score,
to determine whether the score is better than its parts at pre-
dicting disease progression.
Fourth, to demonstrate the utility of the AD severity score
for predicting future levels of biomarkers, we evaluated the
association of changes in biomarker levels with baseline
levels of AD severity using regressions of each biomarker
on AD severity, time, and their interaction. We included
random effects for intercept and slope. We graphed model-
estimated levels of each biomarker against time by quintile
of baseline AD severity to examine whether the trajectory
of the biomarkers varies according to baseline levels of
AD severity.
2.4.3. Sensitivity analyses
Different uses of an AD severity score (e.g., screening
and tracking progression in preclinical cases vs.
describing trajectories) place different demands on the
level of measurement precision needed at particular ranges
of severity that are in turn informed by different measures.Table 1
Baseline characteristics of the ADNI and BIOCARD samples
Characteristic
ADNI
Mean (SD) or number (%
Sample size 822
Age at baseline, mean (SD) 75.3 (6.9)
Race/ethnicity, n (%)
White 748 (91.0)
Black 38 (4.6)
Hispanic 20 (2.4)
Other/unknown 16 (1.9)
Female sex, n (%) 344 (41.9)
Years of education, mean (SD) 15.5 (3.0)
Study visits, n (%) 6.0 (2.8)
Years of follow-up, mean (SD) 3.9 (2.7)
Mini-mental state examination score, mean (SD) 26.7 (2.7)
Baseline diagnosis, n (%)
Normal 229 (27.9)
MCI 400 (48.7)
Dementia 193 (23.5)
Incident MCI, n (%) 73 (8.9)
Incident AD dementia, n (%) 242 (38.5)
Biomarker levels, mean (SD)
Ab1–42 144.4 (56.3)
Phosphorylated tau 28.4 (18.6)
Hippocampal volume 2297.3 (528.2)
Digit symbol substitution test 47.0 (13.1)
Auditory verbal learning test, sum of recall 43.5 (11.5)
FAQ 6.0 (6.6)Latent trait theory leads to the expectation that the same
level of AD severity can be obtained if only a subset of
the disease severity markers are observed. Thus, we con-
ducted a series of leave-1-out measurement models which
omitted a biomarker and re-estimated the AD severity
score. We compared scores with Bland–Altman plots to
evaluate precision and bias across the range of underlying
AD severity [29]. Results of this sensitivity analysis
informed the minimum set of biomarkers that can be as-
sessed to return a reasonably precise estimate of a person’s
underlying AD severity.3. Results
ADNI-1 is a diagnostically heterogeneous sample of
822 older adults (mean age, 73 years, range 54–91 years)
that at baseline included cognitively normal (N 5 229),
MCI (N 5 400), and AD dementia cases (N 5 193)
(Table 1). During follow-up on average of 4 years (range
0 to 9 years, median 3 years), N 5 73 progressed from
cognitively normal to MCI and N 5 242 progressed to
AD dementia. BIOCARD is a younger sample (58 years,
range 20 to 85 years) than ADNI and at baseline included
mostly cognitively normal persons (N 5 284, 84.8%).
During follow-up on average of 11.5 years (range, 0–
17.8 years, median 12.1 years), N 5 79 participants pro-
gressed to MCI and N 5 28 to dementia.BIOCARD
) Range Mean (SD) or number (%) Range
349
54.8–90.9 57.6 (10.0) 20.4–84.8
336 (96.6)
5 (1.4)
4 (1.1)
3 (0.9)
201 (57.6)
4–20 17 (2.4) 12–20
1–12 8.3 (4.0) 1–18
0–9.1 11.5 (4.9) 0–17.8
18–30 29.5 (0.9) 27–30
279 (84.5)
30 (9.1)
21 (6.4)
79 (22.4)
28 (8.0)
1–266.7 259.3 (113.5) 25.1–555.4
2.0–109.0 32.2 (23.2) 4.5–158.4
187.5–3772.4 765.7 (280.6) 81.0–1361.7
4.0–84.0 44.2 (10.8) 18.0–66.0
7.0–76.0 36.9 (14.6) 8.3–69.9
1.0–31.0 2.8 (5.5) 1.0–28.0
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Measurement models fit the observed data acceptably in
ADNI based on empirical r2 statistics (Table 2). Empirical r2
statistics describe the proportion of variance in each indicator
explained by the model. In ADNI, factor loadings were high-
est for the AVLTand FAQ.Owing tomissing data by design in
BIOCARD, factor loadings and empirical r2 statistics were
lower than in ADNI, particularly for hippocampal volume
and the FAQ, but the empirical r2 were still acceptable.3.2. Model validation
In Table 3, the AD severity score in ADNI distinguishes
AD dementia from cognitively normal persons (area under
the curve, AUC 5 0.98), cognitively normal from MCI
(AUC 5 0.88), and MCI from AD dementia
(AUC 5 0.79). Results were equally good in BIOCARD.
Table 3 also provides classification quality for each disease
severity marker. In both ADNI and BIOCARD, the AD
severity summary score demonstrated equal or superior
sensitivity, specificity, and AUC statistics compared to its
component measures for all comparisons.
Table 4 shows hazard ratios from survival analyses for
associations of the AD severity factor as well as its compo-
nents and time-to-progression to MCI or to AD dementia.
Hazard ratios explain the elevated risk of progression per
unit difference in the AD severity factor or its components.
Because the variables are in different units, we also present
z statistics for the hazard ratios to facilitate comparisons of
the relative strength of the hazard ratios. In ADNI data, in
which participants contributed 3153 person-years, relative
to the individual components of the severity factor, theTable 2
Factor loadings for AD Severity: Results from ADNI (N 5 822) and BIOCARD
Biomarker
Standardized
loading
Thresholds
1 2
ADNI (N 5 822, 4949 observations)
Ab1–42 0.54 21.63 20.92
Phosphorylated tau 0.48 21.35 20.67
Hippocampal volume 0.58 22.20 21.06
Digit symbol substitution test 0.64 22.59 21.69
Auditory Verbal Learning Test, sum
of recall
0.77 22.29 21.84
FAQ 0.76 20.29 0.31
BIOCARD (N5 349, 2773 observations)
Ab1–42 0.36 0.69 0.84
Phosphorylated tau 0.35 0.33 0.99
Hippocampal volume 20.05 21.59 21.11
Digit symbol substitution test 0.47 21.27 20.47
California verbal learning test, sum
of recall
0.56 21.27 20.61
FAQ 0.26 1.01 1.21
NOTE. Standardized factor loadings represent correlations between an item and
cut points on the scale of the latent trait. Empirical r2 statistics are the squared co
values of the indicator in the data and are used here to indicate quality of item-leAD severity factor was most strongly associated with onset
of dementia (hazard ratio [HR]5 1.08; 95% confidence in-
terval [CI], 1.07–1.10; Z 5 9.94), followed by AVLT and
hippocampal volume (both HR 5 1.08; 95% CI, 1.6–
1.09). In BIOCARD, in which participants contributed
3312 person-years, the AD severity score predicted pro-
gression to AD dementia (HR 5 1.05; 95% CI, 1.00–
1.10; Z 5 2.10) but not to MCI (HR 5 0.98; 95% CI,
0.95–1.02; Z 5 20.88).
To evaluate construct validity, the power of the AD
severity score to distinguish differences in the pace of change
in AD severity is illustrated in Figs. 1 (ADNI) and 2 (BIO-
CARD). These figures summarize the longitudinal trajectory
of a random sample of individual persons’ AD severity scores
over age. Values plotted are best unbiased linear predictors
based on a linear mixed effect regression model of predicted
AD severity score. Four groups of participant’s trajectories
are summarized in these figures: those who begin cognitively
normal and remain normal (solid blue lines), those who begin
with MCI and remain MCI (solid green lines), those who
begin with clinical AD dementia and do not worsen (solid
red lines), and thosewho progress to a higher level of severity
(solid black lines) over follow-up. The average trajectory for
persons who are normal, MCI, and AD dementia at baseline
and who progressed are shown with thicker blue, green, red,
and black lines, respectively. For persons who progressed,
colored dots indicate current (at time of assessment) clinical
stage as indicated in the key. In Fig. 2 for BIOCARD, we did
not plot average trajectories for AD dementia or MCI cases
because, by design, no participants had such a diagnosis at
baseline.
Figs. 1 and 2 suggest that among older persons who are
cognitively normal and remain so over up to 9 years in(N 5 349)
Empirical r23 4 5 6 7 8
20.59 20.45 0.01 0.57 1.00 1.78 0.85
20.16 0.19 0.65 0.88 1.33 1.71 0.78
20.43 20.17 0.21 0.71 1.17 1.91 0.97
21.06 20.32 0.40 1.02 1.64 2.11 0.97
21.14 20.55 0.14 1.08 1.88 2.63 0.98
0.66 0.91 1.25 1.42 1.68 1.98 0.98
0.99 1.16 1.34 1.52 1.86 2.11 0.65
1.15 1.36 1.49 1.62 2.02 2.18 0.62
20.44 0.01 0.22 0.6 0.86 1.56 0.58
0.22 0.97 1.57 1.91 2.06 2.13 0.92
0.05 0.58 1.04 1.51 1.94 2.35 0.96
1.47 1.54 1.63 1.68 1.73 1.94 0.86
the underlying latent trait. Standardized thresholds represent the location of
rrelations between model-estimated values of each indicator and observed
vel fit of the model to the data.
Table 3
Criterion validity of the AD severity factor using diagnostic status: Results from ADNI (N 5 822) and BIOCARD (N 5 349)
Data set and diagnostic comparison Predictor Area under the curve Sensitivity Specificity
ADNI (N 5 822)
Normal vs AD
AD severity factor 0.98 0.96 0.94
Ab1–42 0.83 0.83 0.76
Phosphorylated tau 0.76 0.69 0.72
Hippocampal volume 0.90 0.80 0.83
Digit symbol substitution 0.91 0.83 0.85
Auditory verbal learning 0.96 0.91 0.89
FAQ 0.97 0.93 0.95
Normal vs MCI
AD severity factor 0.88 0.79 0.85
Ab1–42 0.73 0.69 0.72
Phosphorylated tau 0.65 0.61 0.63
Hippocampal volume 0.77 0.66 0.77
Digit symbol substitution 0.74 0.65 0.72
Auditory verbal learning 0.84 0.75 0.79
FAQ 0.84 0.79 0.83
MCI vs AD
AD severity factor 0.79 0.77 0.70
Ab1–42 0.60 0.68 0.48
Phosphorylated tau 0.61 0.65 0.51
Hippocampal volume 0.67 0.65 0.61
Digit symbol substitution 0.73 0.69 0.64
Auditory verbal learning 0.72 0.64 0.68
FAQ 0.78 0.79 0.67
BIOCARD (N 5 349)
Normal vs AD
AD severity factor 0.99 0.95 0.96
Ab1–42 0.96 1.00 0.93
Phosphorylated tau 0.86 0.82 0.88
Hippocampal volume 0.67 0.71 0.68
Digit symbol substitution 0.93 0.80 0.91
California verbal learning 0.94 0.88 0.88
FAQ 0.97 0.95 0.98
Normal vs MCI
AD severity factor 0.78 0.73 0.65
Ab1–42 0.78 0.68 0.80
Phosphorylated tau 0.67 0.55 0.80
Hippocampal volume 0.64 0.60 0.68
Digit symbol substitution 0.76 0.67 0.73
California verbal learning 0.78 0.72 0.71
FAQ 0.63 0.30 0.96
NOTE. Each row is based on a separate logistic regression of diagnostic status on the predictor (row) of interest. Logistic regressions account for clustering of
observations within people over time using a Huber–White variance estimator.
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severity is slow but positive. Persons initially enrolled with
clinical AD dementia begin in a much more impaired range
at baseline, yet possibly due to ceiling effects, selection
effects, or drop-outs their pace of change is comparable to
cognitively normal persons. The pace of change among
people with MCI and those who progressed to a higher level
of severity is steeper than in other groups.
Supplementary Figs. 1 (ADNI) and 2 (BIOCARD)
show results of random effects regressions of each
biomarker on baseline levels of the AD severity score
by quintile of AD severity. The trajectories for each dis-
ease severity marker are not parallel, indicating the ADseverity score at baseline partially differentiates trajec-
tories of disease severity markers.3.3. Sensitivity analyses
We evaluated the extent to which an accurate latent trait
score can be estimated with subsets of available biomarkers
(e.g., if Ab1–42 is unavailable, if hippocampal atrophy is un-
available). Bland–Altman plots of factor scores from leave-
1-out models for each disease severity marker revealed
minimal evidence of systematic bias over the range of AD
severity (Supplementary Figs. 3 and 4). These results depict
Table 4
Predictive convergent validity of the AD severity factor: Results from ADNI (N 5 822) and BIOCARD (N 5 349)
Predictor Number of progressors Hazard ratio 95% confidence interval Z statistic
BIOCARD: Progression to MCI
AD severity factor 32 0.98 0.94–1.02 21.02
Ab1–42 18 1.02 0.97–1.07 0.94
Phosphorylated Tau 18 1.09* 1.03–1.15 2.94
Hippocampal volume 19 1.01 0.96–1.06 0.33
Digit Symbol Substitution 23 1.11* 1.05–1.18 3.76
California Verbal Learning 9 1.14* 1.01–1.28 2.21
FAQ 0 —
BIOCARD: Progression to Dementia
AD Severity factor 12 1.05* 1.00–1.10 2.10
Ab1–42 9 1.07* 1.01–1.14 2.18
Phosphorylated Tau 9 1.12* 1.04–1.20 3.10
Hippocampal volume 10 1.07 0.97–1.17 1.42
Digit Symbol Substitution 12 1.11* 1.03–1.21 2.62
California Verbal Learning 0 —
FAQ 0 —
ADNI: Progression to Dementia
AD Severity factor 176 1.08* 1.07–1.10 9.96
Ab1–42 92 1.07* 1.04–1.09 5.23
Phosphorylated Tau 92 1.04* 1.02–1.05 3.73
Hippocampal volume 171 1.08* 1.07–1.10 9.15
Digit symbol substitution 176 1.04* 1.03–1.06 5.97
Auditory verbal learning 176 1.08* 1.06–1.10 8.95
FAQ 175 1.03* 1.01–1.04 4.08
NOTE. The AD severity score for BIOCARDwas based on a model in which ADNI parameters were applied to the BIOCARD sample. Because the variables
are in different units, z statistics facilitate comparisons of the relative strength of the hazard ratios. Each row is based on a separate logistic regression of diag-
nostic status on baseline levels of the predictor (row) of interest. All models are adjusted for age.
*P , .05.
A.L. Gross et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 4 (2016) 159-168 165that reasonable measurement precision of AD severity for
research use can be obtained with any five of the six markers.
In another sensitivity analysis, we estimated factor ana-
lyses based on normalized versions of the disease severity
markers (Supplementary Table 1). Factor loadings from
these models in ADNI and BIOCARD were similar to their
counterparts using discretized indicators.4. Discussion
The overarching goal of this project was to develop an
objective and quantitative method for integrating multiple
biomarkers of AD into a global measure of AD severity.
We incorporated cerebrospinal fluid, structural neuroimag-
ing markers, neuropsychological testing, and functional per-
formance into a latent trait model. The AD severity score is a
content-valid measure of AD severity. Results suggest it a
reasonable approach for describing individual differences
in AD severity and predicts progression from cognitively
normal to more impaired clinical states. These findings sug-
gest the approach can characterize underlying severity of
disease and may therefore be useful for drug development
or evaluating response to treatment.
Our derived AD severity score has potential to advance
AD research by providing a method for characterizing the
level of severity of AD in both preclinical and symptomatic
cases. Because AD is recognized as a disease that developsover decades with a long preclinical period and in the
absence of apparent clinical symptoms, a summary severity
score based on biomarkers will be essential for screening and
targeting of early interventions. Most current clinical trials
are using amyloid imaging to determine whether AD pathol-
ogy is present. However, such a method is not optimal for
grading disease severity. An objective statistical measure
of AD severity offers a feasible way to shorten clinical trials
by providing a method to capture underlying pathology that
can be tracked longitudinally.
Our model is based on available biomarkers and is ex-
tendible. Future work that identifies new biomarkers can
be incorporated into the model and provide greater precision
or information regarding AD severity. For example, our
model uses CSFAb1–42 and P-Tau, but future investigations
might instead use the ratio of Ab1–42/P-Tau. Our study’s pur-
pose was not to build a predictive model of AD diagnosis;
thus, we did not consider demographic or genetic modifiers
of AD risk in measurement models. Age, sex, and APOE sta-
tus are not part of the dynamic biomarkers hypothesis [1],
and AD does not cause these characteristics. Age, sex, and
APOE status are important features to include when trying
to predict AD progression and conversion, but they are not
appropriate factors to include as indicators that define AD
severity.
Another future direction for the field, outside the scope of
the present analysis, will be to compare the relative strength
Fig. 1. Longitudinal trends in Alzheimer disease severity in ADNI. This
figure shows a random sample of longitudinal trajectories for select ADNI
subgroups. Persons who begin the study in the normal group and do not
progress over 48M follow-up are shown with solid blue lines without
markers (dots). The average trajectory for this group is shown with a heavy
blue-dashed line. Persons who begin with clinical AD are shown in solid red
lines. The trend line for this group is shown with a heavy dashed red line.
Persons who progress (either from normal to mild cognitive impairment
(MCI) or AD or from MCI to AD are drawn with black lines, and colored
dots indicate their current (at time of assessment) clinical stage as indicated
in the key. The average trajectory for this group is shown with a solid black
line. The values plotted are best unbiased linear predictors based on a linear
mixed effect regression model of predicted Alzheimer disease severity
score.
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models to predict onset of AD and characterize trajectories
of AD severity. Such alternative models include the AD
signature based on MRI [30], Jednyak et al. [8] disease pro-Fig. 2. Longitudinal trends in Alzheimer disease severity in BIOCARD.
This figure shows a random sample of longitudinal trajectories for select
BIOCARD subgroups. Persons who begin the study in the normal group
and do not progress during follow-up are shownwith solid blue lines without
markers (dots). The average trajectory for this group is shown with a heavy
blue-dashed line. Persons who progress (either from normal to mild cogni-
tive impairment (MCI) or AD or from MCI to AD are drawn with black
lines, and colored dots indicate their current (at time of assessment) clinical
stage as indicated in the key. The average trajectory for this group is shown
with a solid black line. The values plotted are best unbiased linear predictors
based on a linear mixed effect regression model of predicted Alzheimer dis-
ease severity score.gression model for AD which bears some resemblance to
ours in terms of goal, and a recently proposed spatiotemporal
function to simultaneously model the ordering of a multifac-
torial set of biomarkers in late-onset AD [31].
Strengths of the study include two well-characterized co-
horts followed prospectively for years. Strengths of our anal-
ysis include the use of readily available standard software,
with standard expectations for conduct of analysis and re-
porting that is an important aspect of reproducibility, thus
reducing the likelihood of false findings [32]. Mplus is flex-
ible and provides a framework for testing alternative models
(e.g., a nonlinear relationship between underlying AD
severity and a biomarker could be tested with a latent vari-
able interaction).
A noteworthy study limitation is that some aspects of the
study designs for ADNI and BIOCARD are not ideal for the
inferences we sought to make. It would be helpful to have
AD severity indicator data for even younger ages, possibly ex-
tending back as far as 40years of age or evenyounger. Itwould
also have been better if clinically normal participants inADNI
were a random selection from the population. We addressed
the issue of younger ages, in part, by applying our findings
to the BIOCARD study, but even there participants were not
selected to be a random population sample, as it was enriched
with people who had a family history of dementia.
Another potential study limitation is our discretization of
AD severity markers that are observed quantitatively. This re-
sults in some loss of information. In a sensitivity analysis, we
reran models using continuous versions of disease severity
markers and currently believe the discretization approach is
better (Supplementary Table 1). The advantage of the discre-
tization approach is that it does not presume that AD severity
increases linearly with increases in the quantitatively
observed biomarker. This comes from estimating eight thresh-
olds for a nine-category discretized biomarker: the spacing
among the estimated thresholds along the latent trait can vary.
A third limitation is that the extent to which a model-
estimated AD severity score corresponds to an assumed un-
derlying reality of an AD pathological process hinges
directly on which AD severity indicators are in the model.
Although ADNI and BIOCARD collected a multitude of
biomarkers, we included a relatively small set. Any number
of AD biomarkers could be chosen for a model such as ours,
and each might produce some differences in the rank
ordering of persons along a continuum of AD severity. For
example, Abeta loads determined by PIB, FDG PET-
derived measures of metabolism, and size and shape of the
corpus callosum are other important markers albeit unavai-
lable in other datasets we used in the present study [33–
35]. Given this, our model can only be seen as a rough
empirical guide to the underlying nature of AD severity,
and suited for group differences research (e.g., testing the
effectiveness of interventions administered to groups;
charting the progression of AD in population samples).
Application to inference at the individual level should be
discouraged. The goal of this study was to introduce the
A.L. Gross et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 4 (2016) 159-168 167concept, methods, and use of the objective measure of AD
severity using biomarkers and other disease severity
markers. Future extensions of our model will be to
investigate the potential utility of other biomarkers, with
an eye toward identifying those with a dynamic range
relevant to persons with very early AD.Acknowledgments
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1. Systematic review: Alzheimer’s disease (AD) develops
over decades, but underlying disease severity is diffi-
cult to measure with individual biomarkers. The dy-
namic biomarkers hypothesis provides a framework
for conceptualizing the pathological cascade of AD
that begins with abnormal amyloid processing and cul-
minates in clinical symptoms and functional disability.
2. Interpretation: Recognizing the dynamic biomarkers
hypothesis as a latent variable model, we present an
objective, quantitative method for integrating multi-
ple biomarkers and other severity indicators of AD
into a global measure encompassing preclinical and
symptomatic disease stages. The derived AD severity
factor distinguishes diagnostic groups as well or bet-
ter than its component AD biomarkers. Worsening
scores predict faster progression to AD dementia
among participants with MCI.
3. Future directions: Potential applications of the
derived severity score include being an intermediate
outcome in clinical trials. The model should addi-
tionally facilitate research on novel biomarkers
which have a dynamic range relevant to persons
with preclinical AD.References
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